Literature DB >> 8807707

Molecular Interactions of Thrombin.

A Tulinsky1.   

Abstract

Thrombin possesses at least three independent binding sites for substrate, inhibitor, and co-factor molecules, four counting the Na+ ion binding site. The S1 subsite of the active site is specific for an arginine side group, while S2 is a more extended apolar site. The highly electropositive S' subsites of the fibrinogen exosite circumnavigate about a third of the thrombin surface, although evidence suggests molecular recognition of a tetra- or pentapeptide sequence is sufficient for binding. Another highly electropositive region of thrombin that binds the second kringle of prothrombin is the heparin binding site. All three of these sites display distinct binding modes with different molecules. These can arise from tolerance of imprecision of binding and/or from reversal of ligand main chain direction in active site and fibrinogen exosite binding. Preliminary indications suggest similar principles may apply to the heparin site. Such varied behavior easily accounts for the diversity of thrombin functions at the molecular level. The complexity of the behavior is compounded even more by a Na+ ion binding site that produces a procoagulant fast form of thrombin. The slow form (in the absence of Na+ ion) is anticoagulant.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807707     DOI: 10.1055/s-2007-998998

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  11 in total

Review 1.  Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.

Authors:  Michael Ganetsky; Kavita M Babu; Steven D Salhanick; Robert S Brown; Edward W Boyer
Journal:  J Med Toxicol       Date:  2011-12

2.  Inhibition of thrombin activity by prothrombin activation fragment 1.2.

Authors:  Swapan Kumar Dasgupta; Perumal Thiagarajan
Journal:  J Thromb Thrombolysis       Date:  2007-03-02       Impact factor: 2.300

Review 3.  Direct thrombin inhibitors.

Authors:  Catherine J Lee; Jack E Ansell
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 4.  Viscoelasticity and Ultrastructure in Coagulation and Inflammation: Two Diverse Techniques, One Conclusion.

Authors:  Albe C Swanepoel; Vance G Nielsen; Etheresia Pretorius
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

5.  In Vitro Antithrombotic, Hematological Toxicity, and Inhibitor Studies of Protocatechuic, Isovanillic, and p-Hydroxybenzoic Acids from Maclura tricuspidata (Carr.) Bur.

Authors:  Jun-Hui Choi; Seung Kim
Journal:  Molecules       Date:  2022-05-29       Impact factor: 4.927

6.  A dimeric form of prothrombin on membrane surfaces.

Authors:  P J Anderson
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

7.  Immobilization of the thrombin inhibitor r-hirudin conserving its biological activity.

Authors:  J Lahann; W Plüster; D Klee; H G Gattner; H Höcker
Journal:  J Mater Sci Mater Med       Date:  2001-09       Impact factor: 3.896

8.  Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.

Authors:  Niyati H Vakil; Abir O Kanaan; Jennifer L Donovan
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01

Review 9.  Bivalirudin in percutaneous coronary intervention.

Authors:  Sam J Lehman; Derek P Chew
Journal:  Vasc Health Risk Manag       Date:  2006

10.  Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies.

Authors:  Deyan Luan; Michael Zai; Jeffrey D Varner
Journal:  PLoS Comput Biol       Date:  2007-07       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.